BMBioMarin Pharmaceutical BMRN · NASDAQ
$58.51 +1.77% (+$1.02)
- Market cap
- $11.1B
- Enterprise value
- $14.5B
- P/E
- 152.5x
- Forward P/E
- -
- PEG
- -
- P/S
- 3.3x
- P/FCF
- 15.2x
- EV/EBITDA
- 37.5x
- ROIC
- 1.2%
- Gross margin
- 75.5%
- Net margin
- 2.1%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- 8.6x
- Beta
- 0.22
- Free float
- 99.5%
About the company
BioMarin Pharmaceutical Inc. (BMRN) is an American biopharmaceutical company specializing in the research, development, and manufacturing of drugs for rare genetic diseases and rare disorders. With a broad portfolio of medicines serving the needs of patients with genetically determined disorders, BioMarin is a leading innovator in the treatment of genetic diseases. The company is known for its pioneering therapeutic approaches and longstanding commitment to patients with rare diseases. BioMarin also actively invests in the research and development of new drugs and therapies to improve the quality of life for patients. BioMarin Pharmaceutical Inc. (BMRN) shares could be suitable for investors looking to invest in the biopharmaceutical sector with a focus on treating rare genetic diseases and innovative research and development.
Sector
Healthcare
Industry
Biotechnology
CEO
Alexander Hardy
Employees
3,221
Headquarters
San Rafael
Valuation
Is today's price reasonable?
- What to watch: The share price is above the Bulios Fair Price.
Growth and estimates
Is it growing, and what comes next?
- What speaks for it: Earnings per share grew by 34% a year over the last 3 years.
- What speaks for it: Analysts expect revenue to grow by 22% this fiscal year.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What speaks for it: Out of every 100 USD of revenue, 22 USD is left as free cash.
- What to watch: Out of every 100 USD of revenue, only 2.1 USD is left as net profit.
- What to watch: It earns only 1.2 USD a year on every 100 USD of invested capital.
Financial health
Can it carry its debt?
- What to watch: Repaying its net debt would take 8.6 years of operating profit.
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number